Skip to main content
. 2013 Aug 16;14(8):16917–16942. doi: 10.3390/ijms140816917

Figure 6.

Figure 6

Treatment of AD mice with a predominantly peripheral-acting ACE inhibitor. (a) Hippocampal ACE activity of 12 and 18 month-old Tg2576 mice treated without or with enalapril (Enal) for six months (±s.d.; n = 4 mice/group; ***p < 0.001 and **p < 0.01 vs. Tg-12mo; ANOVA and Tukey’s Multiple Comparison Test); (b) Hippocampal Epha4 content of Tg2576 mice treated without or with enalapril (Enal) was determined by direct binding assay with anti-Epha4 antibodies followed by detection with 125I-labeled secondary antibodies (±s.d.; n = 4 mice/group; ***p < 0.001 and *p < 0.05 vs. Tg-12mo; ANOVA and Tukey’s Multiple Comparison Test); (c) Comparable peripheral ACE inhibition by enalapril and captopril was shown by renal ACE activity measurement of Tg2576 mice treated for six months with captopril (Capto) or enalapril (Enal) as indicated (±s.d.; n = 4 mice/group; ***p < 0.001 vs. Tg-18mo; ANOVA and Tukey’s Multiple Comparison Test).